ARTIVA BIOTHERAPEUTICS INC (ARTV) Stock Fundamental Analysis
NASDAQ:ARTV - Nasdaq - US04317A1079 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to ARTV. ARTV was compared to 559 industry peers in the Biotechnology industry. While ARTV seems to be doing ok healthwise, there are quite some concerns on its profitability. ARTV is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year ARTV has reported negative net income.
ARTV had a negative operating cash flow in the past year.
1.2 Ratios
ARTV has a Return On Assets (-37.50%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -42.49%, ARTV is in the better half of the industry, outperforming 69.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.5% | ||
| ROE | -42.49% | ||
| ROIC | N/A |
ROA(3y)-34.23%
ROA(5y)N/A
ROE(3y)-55.15%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ARTV so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARTV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ARTV has more shares outstanding
Compared to 1 year ago, ARTV has a worse debt to assets ratio.
2.2 Solvency
ARTV has an Altman-Z score of -0.97. This is a bad value and indicates that ARTV is not financially healthy and even has some risk of bankruptcy.
ARTV has a Altman-Z score of -0.97. This is comparable to the rest of the industry: ARTV outperforms 59.75% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ARTV is not too dependend on debt financing.
ARTV has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.97 |
ROIC/WACCN/A
WACC15.99%
2.3 Liquidity
ARTV has a Current Ratio of 13.93. This indicates that ARTV is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ARTV (13.93) is better than 85.69% of its industry peers.
A Quick Ratio of 13.93 indicates that ARTV has no problem at all paying its short term obligations.
The Quick ratio of ARTV (13.93) is better than 85.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.93 | ||
| Quick Ratio | 13.93 |
3. Growth
3.1 Past
ARTV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -370.69%.
The Revenue for ARTV has decreased by -99.25% in the past year. This is quite bad
Measured over the past years, ARTV shows a very negative growth in Revenue. The Revenue has been decreasing by -49.95% on average per year.
EPS 1Y (TTM)-370.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-39.11%
Revenue 1Y (TTM)-99.25%
Revenue growth 3Y-49.95%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
The Earnings Per Share is expected to grow by 13.29% on average over the next years. This is quite good.
ARTV is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -25.99% yearly.
EPS Next Y39.02%
EPS Next 2Y19.1%
EPS Next 3Y13.29%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ARTV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARTV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ARTV's earnings are expected to grow with 13.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.1%
EPS Next 3Y13.29%
5. Dividend
5.1 Amount
No dividends for ARTV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.98
-0.07 (-3.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners84.81%
Inst Owner Change-0.92%
Ins Owners0.91%
Ins Owner Change7.9%
Market Cap48.23M
Analysts85
Price Target17.34 (775.76%)
Short Float %7.63%
Short Ratio3.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.12%
Min EPS beat(2)-14.53%
Max EPS beat(2)14.3%
EPS beat(4)2
Avg EPS beat(4)-90.39%
Min EPS beat(4)-390.47%
Max EPS beat(4)29.15%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.67%
PT rev (3m)-19.05%
EPS NQ rev (1m)-13.96%
EPS NQ rev (3m)-6.94%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.29 | ||
| P/tB | 0.29 | ||
| EV/EBITDA | N/A |
EPS(TTM)-24.15
EYN/A
EPS(NY)-3.15
Fwd EYN/A
FCF(TTM)-2.5
FCFYN/A
OCF(TTM)-2.45
OCFYN/A
SpS0
BVpS6.93
TBVpS6.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.5% | ||
| ROE | -42.49% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-34.23%
ROA(5y)N/A
ROE(3y)-55.15%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 45.91% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 13.93 | ||
| Quick Ratio | 13.93 | ||
| Altman-Z | -0.97 |
F-Score2
WACC15.99%
ROIC/WACCN/A
Cap/Depr(3y)238.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)131.08%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-370.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-39.11%
EPS Next Y39.02%
EPS Next 2Y19.1%
EPS Next 3Y13.29%
EPS Next 5YN/A
Revenue 1Y (TTM)-99.25%
Revenue growth 3Y-49.95%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y-119.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.03%
OCF growth 3YN/A
OCF growth 5YN/A